The Assistant Controller/Controller (consultant role) will oversee the maintenance of the Company’s financial and accounting departments. This is a hands-on role for a technically strong accounting professional who can navigate complex biotech transactions, manage a team, and improve processes in a lean organization. The Assistant Controller/Controller (Consultant role) will partner across Finance and the business, balancing public-company rigor with practical, efficient execution.
Responsibilities
- Own the monthly, quarterly, and annual close, reconciliations, and internal management reporting; ensure accurate and complete accounting records in accordance with U.S. GAAP.
- Oversee the accounting components of Clinical/R&D accruals, prepayments, commitments, and program-level expenses, including review of estimates, journal entries, reconciliations, and true-ups.
- Own and review SEC filings (Forms 10-K, 10-Q, and 8-K, and proxy statements), ensuring compliance with applicable SEC disclosure requirements; proficiency in Active Disclosure or a similar reporting platform is preferred.
- Lead the Company’s equity compensation program and stock-based compensation accounting, including option, RSU, and ESPP activity, ASC 718 accounting, and common share/equity pool reconciliations.
- Partner with Clinical Operations, Technical Operations, and FP&A to establish supportable accruals for contract research organizations, contract manufacturers, and investigator sites using contracts, operational progress, and vendor data.
- Lead SOX and internal control activities within accounting, including risk assessment, documentation, testing, and remediation.
- Support management assessments and external auditor attestation under SOX Section 404.
- Partner with IT and business process owners on access, segregation of duties, and related controls.
- Serve as the primary accounting contact for external and internal auditors; coordinate audit and quarterly-review support for accounting operations and SOX testing.
- Oversee payroll and employee benefits accounting, including review of payroll-related journal entries, accrued compensation, bonuses, stock-based compensation, and employee benefit costs
- Manage the Company’s corporate insurance programs, including policy renewals, coverage reviews, premium negotiations, coordination with brokers and insurance carriers, and ensuring appropriate coverage for the Company’s evolving business needs.
- Oversee General Ledger, Accounts Payable, disbursements, fixed assets, and expense processes.
- Maintain effective invoice processing, payment-approval, and disbursement controls.
- Support income tax provision and compliance activities by providing accurate accounting records and schedules to the responsible internal teams and external advisors.
- Lead, mentor, and develop the accounting team and manage accounting service providers.
- Establish clear accountability, cross-training, and professional development opportunities.
- Partner with Finance team to provide reliable actuals, accruals, and insights for budgeting, forecasting, cash planning, and liquidity assessments.
- Provide accounting analysis and due diligence support for financing, partnerships, and other corporate transactions. Communicate complex issues clearly and raise risks early with practical recommendations.
Qualifications
- Bachelor’s degree in Accounting, Finance, or related discipline; CPA required; Big Four experience preferred.
- 10+ years of progressive accounting experience, including at least 3 years leading teams and significant experience within a U.S. publicly traded biotechnology or life sciences company.
- Prior hands-on experience in an operational accounting role, including direct responsibility for leading public-company accounting operations, the financial close, preparation of accounting analyses, SEC reporting, audit support, and SOX compliance.
- Proficiency with ERP and accounting and payroll systems; advanced Excel skills and a track record of improving close, accrual, and internal reporting processes and data quality. Proficient in NetSuite, , Coupa, Concur, ADP, E-Trade and Active Disclosure (or other similar platforms).
- Demonstrated success developing teams and influencing cross-functional partners in a lean environment. Strong analytical and communication skills, sound judgment, integrity, and the confidence to challenge assumptions and uphold accounting standards.
Skills Required
- Bachelor's degree in Accounting, Finance, or a related discipline
- CPA certification
- 10+ years of progressive accounting experience
- At least 3 years of experience leading teams
- Significant experience within a U.S. publicly traded biotechnology or life sciences company
- Hands-on operational accounting experience, including public-company accounting operations, financial close, accounting analysis, SEC reporting, audit support, and SOX compliance
- Proficiency with ERP, accounting, and payroll systems
- Advanced Microsoft Excel skills
- Proficiency in NetSuite, Coupa, Concur, ADP, E-Trade, and Active Disclosure or similar platforms
- Big Four experience
- Experience improving close, accrual, internal reporting, and data-quality processes
- Experience developing teams and influencing cross-functional partners in a lean environment
- Strong analytical, communication, judgment, integrity, and accounting-standard enforcement skills
What We Do
We are a biopharmaceutical company focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure and the ability to drive a deeper, more durable response. We are utilizing our proprietary FUSION™ System to discover, design and develop a pipeline of next-generation covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Our lead product candidate, BMF-219, is an orally bioavailable, potent and selective covalent inhibitor of menin, an important transcriptional regulator known to play a direct role in in regulating the growth of beta cells in the pancreas as well as oncogenic signaling in multiple cancers. Beyond BMF-219, we are utilizing our novel platform to develop treatments against other high-value metabolic diseases and oncogenic drivers of cancer. We entered the clinic with our second development candidate, BMF-500, a covalent inhibitor of FLT3 and are studying BMF-500 in acute leukemia patients. We also announced our third development candidate, an oral, small molecule GLP-1 receptor agonist in obesity. All our molecules, BMF-219, BMF-500, and our GLP-1 receptor agonist were developed in-house by the Biomea team. We aim to have an outsized impact on the treatment of disease for the patients we serve. We aim to cure. The name biomea derives from the Greek word bios, meaning “life,” and the Latin word mea, meaning “my.” At Biomea Fusion, we develop medicines to improve the life of the individual. Visit us at biomeafusion.com









